XOMA(XOMA) - 2024 Q3 - Quarterly Results

Exhibit 99.1 XOMA Royalty Reports Third Quarter 2024 Financial Results and Highlights Recent Activities Zevra's MIPLYFFA™ (arimoclomol) received FDA approval and became the sixth commercial asset in XOMA Royalty's portfolio XOMA Royalty acquired a 50 percent economic interest in TWIST Bioscience's portfolio of 60-plus licensed early-stage assets across approximately 30 partners Cash receipts totaled $9.9 million in the third quarter, and $42.3 million for the first nine months of 2024 EMERYVILLE, Calif. – N ...